365Telugu.com online news,Hyderabad,April 8th, 2024: Gland Pharma Limited ( Gland or Company), a generic injectable-focused pharmaceutical company, has received approval from the United States Food and Drug Administration (USFDA) for Eribulin Mesylate Injection, 0.5 mg/mL Single Dose Vial (Product).
The Product is expected to be the first generic approval on the market, and the Company expects to launch this product in the near term through its marketing partner.
The Product has US sales of approximately USD 92 million for twelve months ending in February 2024, according to IQVIA.
The Company is co-developing several complex injectables, including this Product, with Orbicular Pharmaceutical Technologies Private Limited.
Also read : MG Motor India, Adani TotalEnergies E-Mobility sign MoU to strengthen EV ecosystem
ఇది కూడా చదవండి: ప్రపంచంలోని అత్యంత వృద్ధుడిగా జాన్ ఆల్ఫ్రెడ్ టిన్నిస్వుడ్ రికార్డు..
Also read : Tata Advanced Systems Limited and Satellogic Announce TSAT-1A Satellite Launch Success..
ఇది కూడా చదవండి: చెడు కర్మలు మంచి కర్మలుగా మారాలంటే ఏమి చేయాలి..?
ఇది కూడా చదవండి: లేటెస్ట్ ఫీచర్స్ తో Samsung Galaxy M55 5G ఫోన్..
ఇది కూడా చదవండి:Redmi Turbo 3 డిజైన్ అండ్ ప్రారంభ తేదీ..?